Ces radiol. 2024, 78(2):132-136 | DOI: 10.55095/CesRadiol2024/018

Serum markers and imaging methods in pancreatic neuroendocrine tumors

Veronika Roškovičová1, Viliam Weis2, Jana Kaťuchová1, Viera Lehotská3
1 I. chirurgická klinika LF UPJŠ, Košice, Slovenská republika
2 Klinika radiologie a zobrazovacích metód (KraZM) Univerzitná nemocnica L. Pasteura, Košice, Slovenská republika
3 Onkologicky ústav sv. Alžbety, Bratislava, Slovenská republika

As the incidence of neuroendocrine tumors increases, so does the diagnosis. Inthe 21st century, diagnosis relies mainly on imaging tests supplemented withserum biomarkers, which can reveal a specific tumor subtype already in itsearly stages. Many times, however, neuroendocrine tumors are an incidentalfinding due to the asymptomatic nature of imaging examinations. In the article,we deal with general serum biomarkers and subsequently basic imagingexaminations used in asymptomatic neuroendocrine tumors and functional imagingmethods used in symptomatic neuroendocrine tumors.

Keywords: neuroendocrine tumor, pancreas, diagnostics, marker

Published: June 1, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roškovičová V, Weis V, Kaťuchová J, Lehotská V. Serum markers and imaging methods in pancreatic neuroendocrine tumors. Ces radiol. 2024;78(2):132-136. doi: 10.55095/CesRadiol2024/018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surgical Clinics of North America 2019; 99(4): 793-814. Go to original source... Go to PubMed...
    2. Kumar S, Senapati S, Bhattacharya N, et al. Mechanism and recent updates on insulin-related disorders. World Journal of Clinical Cases 2023; 6(25): 5840-5856. Go to original source... Go to PubMed...
    3. Jenss H. Siegfried Oberndorfer und das Karzinoid. Zr Gastroenterol. 2019; 57(12): 1463-1464. Go to original source...
    4. Oberg K., Eriksson B. Endocrine tumours of the pancreas. Best Practice and Research Clinical Gastroenterology 2005; 19: 753-781 Go to original source... Go to PubMed...
    5. Mihalache O, Doran H, Poiana C, et al. Pancreatic Neuroendocrine Tumors-Case Series and Literature Review. Chirurgia (Bucur) 2019; 114(5): 630-638. Go to original source... Go to PubMed...
    6. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188. Go to original source... Go to PubMed...
    7. Sorbye H, Grande E, Pavel M, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. Journal od Neuroendocrinology 2023; 35(3): 13249. Go to original source... Go to PubMed...
    8. Pulvirenti A, Rado D, McIntyre CA, et al. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB 2019; 21: 612-618. Go to original source... Go to PubMed...
    9. di Giacinto P, Rota F, Rizza L, et al. Chromogranin A: from laboratory to clinical aspects of patients with neuroendocrine tumors. International Journal of Endocrinology 2018; 8126087. Go to original source... Go to PubMed...
    10. Raoof M, Jutric Z, Melstrom LG, et al. Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors. Surgery 2019; 165(4): 760-766. Go to original source... Go to PubMed...
    11. Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Practice and Research Clinical Endocrinology and Metabolism 2016; 30: 59-77. Go to original source... Go to PubMed...
    12. Adrian TE, Uttenthal LO, Williams SJ, et al. Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. The New England Journal of Medicine 1986; 315: 287-291. Go to original source... Go to PubMed...
    13. Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nature Review Endocrinology 2018; 14: 656-669. Go to original source... Go to PubMed...
    14. Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. Journal of Endocrinological Investigation 2004; 27: 6-11. Go to original source... Go to PubMed...
    15. Kečkéš Š, Palaj J, Waczulíková I, et al. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroentetopancreatic Neuroendocrine Neoplasia. In Vivo 2021; 35(5): 2863-2868. Go to original source... Go to PubMed...
    16. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. British Journal of Cancer 1998; 78: 1102-1107. Go to original source... Go to PubMed...
    17. Nobels FR, Kwekkenboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. The Journal of Clinical Endocrinology and Metabolism 1997; 82: 2622-2628. Go to original source...
    18. Rizzoli SO. Synaptic vesicle recycling: Steps and principles. EMBO Journal 2014; 33(8): 782822. Go to original source... Go to PubMed...
    19. Tomita T. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors. Bosnian Journal of Basic Medical Sciences 2020; 3(20): 336-346. Go to original source... Go to PubMed...
    20. Moller K, Uhlig R, Gorbokon N, et al. Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors, Molecular and Cellular Endocrinology 2024; 581: 112106. Go to original source... Go to PubMed...
    21. Leja J, Essanghir A, Essand M, et al. Novel markers for enterochromaggin cells and gastrointestinal neuroendocrine carcinomas. Modern Pathology 2008
    22. 261-272.
    23. Lee E, O'Keefe S, Leong A, et al. Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment. Journal of Clinical Investigation 2023; 133(20): e167994. Go to original source... Go to PubMed...
    24. Figueroa-Vega N, Diaz A, Adrados M, et al. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocrine-Related Cancer 2010; 17(4): 897-908. Go to original source... Go to PubMed...
    25. Stueven AK, Kayser A, Wetz C, et al. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International Journal of Molecular Sciences 2019; 20(12): 3049. Go to original source... Go to PubMed...
    26. D'Onofrio M, Canestrini S, De RR, et al. CEUS of the pancreas: Still research or the standard of care. Europian Journal of Radiology 2015; 84: 1644-1649. Go to original source... Go to PubMed...
    27. Lee L, Ito L, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Review of Anticancer Therapy 2018; 18(9): 837-860. Go to original source... Go to PubMed...
    28. Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology 2017; 105: 212-244. Go to original source... Go to PubMed...
    29. Zilla A, Arcidiacono PG, Conte D, et al. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. Digestive and Liver Disease 2018; 50: 6-14. Go to original source... Go to PubMed...
    30. Kim JH, Eun HW, Kim YJ, et al. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Europian Radiology 2016; 26: 1338-1347. Go to original source... Go to PubMed...
    31. Takumim K, Fukukura Y, Higashi M, et al. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Europian Journal of Radiology 2015; 84: 1436-1443. Go to original source... Go to PubMed...
    32. Horigushi S, Katto H, Shiraha H, et al., Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm. Journal of Gastroenterology and Hepatology 2017; 32: 925-931. Go to original source... Go to PubMed...
    33. Jeon SK, Lee JM, Joo I, et al. Nonhypervascular Pancreatic Neuroendocrine Tumors: Differential Diagnosis from Pancreatic Ductal Adenocarcinomas at MR ImagingRetrospective Cross-sectional Study. Radiology 2017; 284: 77-87. Go to original source... Go to PubMed...
    34. Ansari NA, Ramalho M, Semelka RC, et al. Role of magnetic resonance imaging in the detection and characterization of solid pancreatic nodules: An update. World Journal of Radiology 2015; 7: 361-374. Go to original source... Go to PubMed...
    35. Guo C, Chen X, Wang Z, et al. Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. Oncotarget 2017; 8: 42962-42973. Go to original source... Go to PubMed...
    36. Ito T, Jensen RT. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Current Opinion in Endocrinology, Diabetes and Obesity 2017; 24: 15-24. Go to original source... Go to PubMed...
    37. Rinzivillo M, Partelli S, Prosperi D, et al. Clinical Usefulness of (18)FFluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. Oncologist 2018; 23(2):186- 92. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content